Amicus Therapeutics, Inc. (FOLD)

NASDAQ: FOLD · Real-Time Price · USD
6.32
+0.33 (5.43%)
At close: Aug 1, 2025, 4:00 PM
6.34
+0.02 (0.40%)
After-hours: Aug 1, 2025, 4:18 PM EDT
5.43%
Market Cap1.95B
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out 308.24M
EPS (ttm)n/a
PE Ration/a
Forward PE42.27
Dividendn/a
Ex-Dividend Daten/a
Volume5,961,603
Open5.93
Previous Close5.99
Day's Range5.93 - 6.35
52-Week Range5.51 - 12.65
Beta0.53
AnalystsStrong Buy
Price Target26.89 (+325.81%)
Earnings DateJul 31, 2025

About CTIC

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration an... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 31, 2007
Employees 499
Stock Exchange NASDAQ
Ticker Symbol FOLD
Full Company Profile

Financial Performance

In 2024, Amicus Therapeutics's revenue was $528.30 million, an increase of 32.29% compared to the previous year's $399.36 million. Losses were -$56.11 million, -62.99% less than in 2023.

Financial Statements

Analyst Summary

According to 10 analysts, the average rating for FOLD stock is "Strong Buy." The 12-month stock price target is $26.89, which is an increase of 325.81% from the latest price.

Price Target
$26.89
(325.81% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200

Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA, targeting $1 billion in revenue by 2028. The DMX-200 licensing deal opens a major market opportun...

11 hours ago - Seeking Alpha

Amicus Therapeutics, Inc. (FOLD) Q2 2025 Earnings Call Transcript

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President of Investor Relations Bradley L. Campbell - CEO...

1 day ago - Seeking Alpha

Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates

Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold ® Q2 Revenue of $128.9M, up 12% at CER Pombiliti ® + Opfolda ® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance includin...

1 day ago - GlobeNewsWire

In NCLA Amicus Win, Eleventh Circuit Vacates SEC Order Used to Fund Its Illegal Collection of Data

American Securities Association and Citadel Securities LLC v. U.S. Securities and Exchange Commission American Securities Association and Citadel Securities LLC v. U.S. Securities and Exchange Commiss...

4 days ago - GlobeNewsWire

Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025

PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, July 31, 2025, at...

11 days ago - GlobeNewsWire

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm

PHILADELPHIA , July 10, 2025 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) ("Amicus") on behalf of the company's shareholders.  Year to da...

22 days ago - PRNewsWire

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan

PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Pombiliti (cipa...

5 weeks ago - GlobeNewsWire

U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts

Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association Food an...

6 weeks ago - GlobeNewsWire

The Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion Therapy

Physician group filed an amicus brief in Chiles v. Salazar defending the right of licensed therapists to offer "conversion therapy" in gender dysphoria.

6 weeks ago - GlobeNewsWire

In NCLA Amicus Win, Supreme Court Revives Innocent Family's Suit over FBI's Wrong-House Raid

Washington, DC, June 13, 2025 (GLOBE NEWSWIRE) -- The U.S. Supreme Court unanimously reversed the Eleventh U.S. Circuit Court of Appeals' dismissal of Martin v. United States, an Atlanta family's Fede...

7 weeks ago - GlobeNewsWire

In NCLA Amicus Win, District Court Topples Kansas Dog Kennel No-Warrant Inspection Regime

Scott Johnson, Harlene Hoyt, Covey Find Kennel, LLC v. Justin Smith, D.V.M., in his official capacity as Animal Health Commissioner at the Kansas Department of Agriculture Scott Johnson, Harlene Hoyt,...

7 weeks ago - GlobeNewsWire

Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma

Amicus Therapeutics is a commercial-stage biotech with a focused pipeline in Fabry, Pompe, and rare kidney diseases. Galafold, its lead therapy, is the only approved oral treatment for Fabry disease a...

7 weeks ago - Seeking Alpha

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL stud...

2 months ago - GlobeNewsWire

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in...

2 months ago - GlobeNewsWire

Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference

PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2025 Health Care Confere...

3 months ago - GlobeNewsWire

Amicus Therapeutics, Inc. (FOLD) Q1 2025 Earnings Call Transcript

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President of Investor Relations Bradley Campbell - Presiden...

3 months ago - Seeking Alpha

Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates

1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in ...

3 months ago - GlobeNewsWire

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS)

3 months ago - GlobeNewsWire

Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025

PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at ...

3 months ago - GlobeNewsWire

Amicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade)

Amicus Therapeutics, Inc., with two approved rare disease therapies, shows strong revenue growth and market potential despite a 30% stock decline since 2021. Galafold and Pombiliti+Opfolda are driving...

4 months ago - Seeking Alpha

In NCLA Amicus Win, D.C. Circuit Recognizes President Trump's Right to Fire Principal Officer

Hampton Dellinger v. Scott Bessent, Secretary of the Treasury, et al. Hampton Dellinger v. Scott Bessent, Secretary of the Treasury, et al.

5 months ago - GlobeNewsWire

NCLA Amicus Brief Asks Fifth Circuit to Maintain Block Against Corporate Transparency Act

Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al. Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al.

5 months ago - GlobeNewsWire

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025

PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i...

5 months ago - GlobeNewsWire

Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call Transcript

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2024 Earnings Conference Call February 19, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - Pres...

5 months ago - Seeking Alpha

Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates

2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webc...

5 months ago - GlobeNewsWire